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Individuals with an at risk mental state (ARMS) are at greatly increased risk of 
developing a psychotic illness. Risk of transition to psychosis is associated with 
regionally reduced cortical gray matter volume. There has been considerable interest in 
the interaction between psychosis risk and substance use. In this study we investigate 
the relationship between  alcohol, cannabis and nicotine use with gray matter volume in 
ARMS subjects and healthy volunteers. Twenty seven ARMS subjects and 27 healthy 
volunteers took part in the study. All subjects underwent volumetric MRI imaging. The 
relationship between regional gray matter volume and cannabis use, smoking, and 
alcohol use in controls and ARMS subjects was analysed using voxel-based 
morphometry. In any region where a significant relationship with drug was present, 
data were analysed to determine if there was any group difference in this relationship. 
Alcohol intake was inversely correlated with gray matter volume in cerebellum, 
cannabis intake was use was inversely correlated with gray matter volume in prefrontal 
cortex and tobacco intake was inversely correlated with gray matter volume in left 
temporal cortex. There were no significant interactions by group in any region. There is 
no evidence to support the hypothesis of increased susceptibility to harmful effects of 
drugs and alcohol on regional gray matter in ARMS subjects. However, alcohol, 
tobacco and cannabis at low to moderate intake may be associated with lower gray 
matter in both ARMS subjects and healthy volunteers – possibly representing low-level 
cortical damage or change in neural plasticity. 
  
Introduction 
Individuals with an At Risk Mental State (ARMS) are at increased risk of developing 
psychosis (Phillips, Yung & McGorry 2000). They have also been shown to have reduced 
gray matter compared to healthy volunteers (Pantelis et al. 2003, Borgwardt et al. 2007), and, 
with transition to psychosis, show a further reduction in gray matter volume (Pantelis et al. 
2003, Takahashi et al. 2009), findings which have been confirmed by recent meta-analyses 
(Smieskova et al. 2010, Fusar-Poli et al. 2011). The cause of these changes is not known, but 
it has been suggested that reductions in gray matter volume might occur, in part, because of 
increased sensitivity in ARMS subjects to the potentially toxic effects of drugs and alcohol 
(Welch et al. 2010). Cannabis, tobacco and alcohol have been implicated in brain volume 
changes in patients with schizophrenia (Sullivan et al. 2000, Nesvag et al. 2007, Szeszko et 
al. 2007, Tregellas et al. 2007, Bangalore et al. 2008, Rais et al. 2008a, McClernon 2009, Van 
Haren et al. 2010), and there is some evidence that moderate levels of intake may be 
associated with reduced gray matter volume in individuals at genetic risk of schizophrenia, 
and even in healthy volunteers (McClernon 2009, Gallinat et al. 2006, Sasaki et al. 2009, 
Verbaten 2009, Lorenzetti et al. 2010). Here, using data acquired during an earlier study 
(Stone et al. 2009), we investigate the hypothesis that the degree of recent cannabis, alcohol 
and tobacco use is negatively associated with gray matter volume in a dose-dependent 
manner, and that ARMS subjects show a stronger negative association between substance use 
and gray matter volume than healthy volunteers due to increased sensitivity to neurotoxic 
effects. 
 
Methods 
Twenty seven ARMS subjects were recruited from OASIS (Outreach and Support in South 
London), part of the South London and Maudsley NHS Trust. Twenty seven age- and sex-
matched controls were recruited from the same geographical area through advertisements that 
outlined the study. Subjects with an ARMS were identified using the Comprehensive 
Assessment of At Risk Mental State (CAARMS) (Yung et al. 2005). All subjects who 
expressed interest in participation were offered a face-to-face interview, where the full details 
of the study, including its possible risks and benefits were explained. Controls had no 
personal history of psychiatric symptoms, psychotropic medication or medical illness, and no 
family history of schizophrenia.  For both groups, exclusion criteria included history of 
severe head injury (loss of consciousness for over 5 minutes), drug or alcohol dependence, 
metallic implants, and pregnancy. 
 
Prior to scanning, all subjects were interviewed about their family and personal psychiatric 
history, current and past medication use and current and past use of alcohol, tobacco and 
illicit drugs. Alcohol use was recorded as the average number of units per week taken in the 
previous month. Tobacco use was recorded as the number of cigarettes taken per day. 
Cannabis use was recorded as the number of times that cannabis was taken in the previous 
year. As the cannabis intake for one ARMS subject was 3 times that of the next heaviest user, 
data on cannabis use were log transformed. 
 
All subjects underwent volumetric MRI scanning. Scanning took place on a General Electric 
(Milwaukee, USA) 3 Tesla HDx Magnetic Resonance system. After positioning the subject in 
the scanner with a foam rest under their knees, an initial localizer scan was performed to 
measure the interhemispheric angle and the AC-PC line (the line passing through the upper 
part of the anterior commisure and the lower part of the posterior commisure – approximated 
from the anterior and posterior corpus callosum).  
 
Structural images were acquired using an axial 2D T2-weighted Fast Spin Echo scan and an 
axial fast FLAIR scan (total scan time 5 minutes), both prescribed parallel to the AC-PC line. 
These were followed by a whole brain 3D coronal IR-SPGR (inversion recovery prepared 
spoiled gradient echo) scan, prescribed from the midline sagittal localizer, giving isotropic 
1.1mm voxel size in a scan time of approximately 6 minutes (TE = 2.82ms; TR = 6.96ms; TI 
= 450ms; flip angle = 20º). 
 
Segmentation was performed using Statistical Parametric Mapping software (SPM5, 
Wellcome Department of Imaging Neurosciences, University College London, UK). Gray 
matter probability images were then “modulated” (to compensate for the effect of spatial 
normalisation) by multiplying each voxel value by its relative volume before and after 
warping. The segmented images were then smoothed with an 8mm x 8mm x 8mm Gaussian 
kernel to reduce noise, and also allow for the effects of small residual mis-registrations.  
 
In order to reduce multiple comparisons, and to correct for the the fact there was a high 
degree of overlap between the use of all three substances, correlations of gray matter volume 
difference with alcohol, cannabis and tobacco intake were analysed in a single model by 
fitting a GLM at each intracerebral voxel in standard space using the BAMM package. Given 
that structural brain changes are likely to extend over a number of contiguous voxels, test 
statistics incorporating spatial information such as 3D cluster mass (the sum of 
suprathreshold voxel statistics) are generally more powerful than other possible test statistics, 
which are informed only by data at a single voxel (Bullmore et al. 1999). A relatively lenient 
p-value (p=0.05) was initially set to detect voxels putatively demonstrating differences 
between groups; spatial clusters of such voxels were then searched for and the “mass” of each 
cluster found (the sum of suprathreshold voxel statistics it comprises) was tested for 
significance. As no parametric distribution is known for cluster mass, permutation based 
testing, implemented in the BAMM package, was used to assess statistical significance at 
both the voxel and cluster levels (Bullmore et al. 1999). At the cluster level, rather than set a 
single a priori p-value below which findings are regarded as significant, the number of 
clusters which would be expected by chance alone for a range of p-values was calculated. 
The statistical threshold for cluster significance for each analysis was then set such that the 
expected number of false positive clusters by chance alone would be less than one (Bullmore 
et al. 1999). Group differences in the relationship between gray matter volume and substance 
use were analysed using a separate GLM implemented in R (Ihaka, Gentleman 1996). 
 
As antipsychotic and antidepressant medication have been reported to affect brain volume 
(Ho et al. 2011, Navari, Dazzan 2009, Smieskova et al. 2009, Moore et al. 2009, Warner-
Schmidt, Duman 2006), we reanalysed the group differences in R excluding ARMS subjects 
who were taking antidepressant or antipsychotic medication at the time of scanning. Lastly, 
to investigate the possibility that the multivariate analysis may have masked some drug 
effects shared by two or more of the substances, we then performed separate post-hoc 
BAMM analyses examining the relationship between gray matter volume and cannabis, 
alcohol and tobacco intake without covariates. 
 
Results 
Demographic details have been reported in an earlier study (Stone et al. 2009). There were no 
significant differences in age, sex, ethnicity, social class or IQ (table 1). Eight ARMS 
individuals but none of the controls had previously taken psychiatric medication and  five of 
these were still taking medication (four had taken quetiapine, but only one was taking it at the 
time of the first scan, one was taking aripiprazole, two were taking citalopram and one was 
taking sertraline) (Stone et al. 2009). ARMS subjects had significantly greater levels of 
psychopathology – including clinically significant anxiety and depressive symptoms (table 
1). All ARMS subjects were offered cognitive behaviour therapy as part of their standard 
care. There were no significant differences in alcohol, cannabis or other illegal substance use 
between healthy volunteers and ARMS subjects, but ARMS subjects smoked more cigarettes 
per day (table 2). In addition to having attenuated psychotic symptoms, three of the ARMS 
subjects also had a first degree relative with schizophrenia, and one had a first degree relative 
with bipolar affective disorder. Four of the ARMS subjects went on to develop a 
schizophreniform psychosis. They had non-significantly higher alcohol (14 compared to 7 
units per week) and tobacco intake (7.5 compared to 5 cigarettes per day) at baseline than the 
non-transition subjects, but did not report any cannabis use in the year prior to their baseline 
assessment. 
 
Alcohol intake was negatively correlated with gray matter volume in cerebellum (beta=-0.03, 
SE=0.01, t=-2.99; p=0.005; fig. 1), cannabis intake was negatively correlated with gray 
matter volume in prefrontal cortex (beta=-1.89, SE=0.59, t=-3.23; p<0.005; fig. 2), and 
number of cigarettes smoked was negatively correlated with gray matter in left temporal 
cortex, parietal cortex and occipital cortex (beta=-0.018, SE=0.005, t=-3.361; p<0.005 ;fig. 
3). These relationships were present in healthy volunteers and ARMS subjects, with no 
significant group interactions. There was one outlier in the alcohol group regression, but after 
removal of this subject, the relationship between alcohol intake and cerebellar gray matter 
was still significant (beta=-0.027, SE=0.020, t=-0.6; p<0.05). Reanalysis of all data excluding 
ARMS subjects who were taking medication at the time of scanning did not significantly 
affect any results: alcohol, cannabis and tobacco use were still significantly related to gray 
matter volumes and there were no significant group interactions. 
 Post-hoc regression analyses excluding covariates revealed significant negative relationships 
with substance use in the same brain regions as reported in the multivariate analysis. In 
addition, alcohol was negatively associated with gray matter volume in parahippocampal 
gyrus, superior temoral gyrus, hippocampus and inferior frontal gyrus; cannabis was 
negatively associated with gray matter volume in cingulate and left insula; and smoking was 
negatively associated with gray matter volume in anterior cingulate, dorsolateral prefrontal 
cortex, insula, temporal cortex and.caudate nucleus (see supplementary material). There were 
no positive associations of gray matter volume with substance use in any brain region. There 
were no significant interactions with group in any of the regions showing a significant 
relationship with substance intake. 
 
Discussion 
We found that heavier use of tobacco, cannabis and alcohol was associated with lower gray 
matter volume in distinct brain regions, but we found no evidence that this relationship was 
more marked in ARMS subjects. This finding contrasts with an earlier study of individuals 
with a genetic risk for schizophrenia, which found that alcohol and cannabis use were both 
associated with gray matter volume reductions in these subjects, but not in controls (Welch et 
al. 2010). Possible reasons for the differences in findings may be that the subjects in the 
present study had a clinical rather than a genetic risk of psychosis and had a lower level of 
substance intake. 
 
In patients with schizophrenia, the relationship between reduced gray matter volume and 
cannabis or alcohol has only been reported in subjects with heavy use or dependence 
(Sullivan et al. 2000, Mathalon et al. 2003), so there may be a threshold above which the 
combined effect of alcohol or cannabis use with psychosis risk becomes associated with 
lower gray matter volume. Alternatively, the differential effects of cannabis use in patients 
with psychosis may only emerge over time. A well designed longitudinal study of patients 
with schizophrenia showed a marked difference in gray matter reductions in patients who 
contiued to take cannabis compared to those who did not (Rais et al. 2008b), whereas this 
finding was not apparent in an earlier cross-sectional study (Cahn et al. 2004). 
 
An increased susceptibility of gray matter volume to tobacco intake has been hypothesised to 
underlie some of the gray matter changes in patients with schizophrenia (Tregellas et al. 
2007). One study supported this hypothesis (Tregellas et al. 2007), but a recent study found 
no association between longitudinal changes in gray matter volume and tobacco intake (Van 
Haren et al. 2010).  In individuals at risk of psychosis, neither the present study, nor the 
earlier study of individuals at genetic risk of schizophrenia (Welch et al. 2010), found any 
evidence for any differential effect of tobacco intake on gray matter volume compared to 
healthy volunteers. 
 
The present finding that low to moderate intake of alcohol and tobacco use are associated 
with gray matter changes in healthy volunteers has been reported in earlier studies, although 
not all reports are in agreement – particularly regarding the brain regions affected. A recent 
systematic review suggests that low levels of alcohol may be associated with reduced gray 
matter volume, particularly affecting frontal brain regions (Verbaten 2009). In the present 
study, the cerebellum was the main region showing reduction in gray matter volume with 
increasing alcohol intake after covarying for smoking and cannabis use, as reported in 
patients with schizophrenia dependent on alcohol (Sullivan et al. 2000). However, in the post-
hoc analysis excluding covariates, reductions in frontal and temporal cortex gray matter were 
also related to increasing levels of alcohol intake. 
 
Our finding of an association between cigarette smoking and reduced gray matter volume in 
parietal and temporal cortices is in keeping with an earlier report that chronic cigarette 
smoking was associated with reduced gray matter volume in these regions in alcohol 
dependent subjects and light drinkers (Gazdzinski et al. 2005). Other studies have reported 
that smokers have reduced gray matter volume in frontal cortex (Brody et al. 2004), as found 
in the current analysis excluding substance use covariates.  
 
The present finding of a prefrontal cortex gray matter reduction associated with cannabis use 
in healthy volunteers is relatively novel. Using a region of interest approach, gray matter 
reductions in medial temporal cortex associated with moderate to heavy cannabis use have 
been reported in healthy volunteers, but individuals studied generally had much higher intake 
of cannabis than in the present study, and negative findings employing the same method have 
also been reported (Lorenzetti et al. 2010, Demirakca et al. 2010). In keeping with the present 
finding, a reduction in N-acetylaspartate (NAA), a marker of neuronal integrity (Moffett et al. 
2007), has been reported in frontal cortex in association with cannabis use in two separate 
studies (Hermann et al. 2007, Cowan, Joers & Dietrich 2009). Reduced prefrontal blood flow 
has also been reported in cannabis users (Martin-Santos et al. 2010). Reduced prefrontal 
blood flow and reduced frontal cortex NAA have also been reported in patients with 
schizophrenia (Hill et al. 2004, Brugger et al. 2010), suggesting that cannabis use may lead to 
similar deficits in neuronal integrity and brain function in prefrontal cortex to those occurring 
in schizophrenia. 
 
The neuropathological basis of the gray matter change detected using MRI, and the clinical 
significance, is unclear, but the reversibility of brain volume changes in patients with alcohol 
dependence has led to suggestions that some of the effects of alcohol on gray matter as 
measured by MRI may be due to non-specific dehydration (Zipursky, Lim & Pfefferbaum 
1989), and it has been demonstrated that dehydration is associated with brain volume 
reductions (Dickson et al. 2005, Kempton et al. 2009). The fact that T2 did not change with 
abstinence (as would be expected with rehydration) argues against this hypothesis, 
however(Schroth et al. 1988). Furthermore, acute administration of alcohol has not been 
shown to increase MRI measures of dehydration (Rooney et al. 2000). Alternatively, gray 
matter differences may reflect regional loss of neurons or changes in neural plasticity, or may 
be due to differences in personality type rather than a direct effect of the drug on brain 
volume (Gardini, Cloninger & Venneri 2009). 
 
There are a number of potential weaknesses of this study that we acknowledge – firstly, the 
study was relatively small, and the range of substance use, particularly for cannabis, was 
fairly limited. Nonetheless, the levels of use reported in this study closely reflect those that 
are common in the population with moderate “social” use, and so any relationship between 
substance use and brain volume suggested by this study may be of significant public health 
interest. Secondly, the questions used to rate substance use did not take into account lifetime 
use, and so associations reported by the present study will reflect recent use. It is unclear 
whether abstinence would lead to an increase in gray matter volume in the affected regions. 
Lastly, a longitudinal design would assist in determining whether continued substance use is 
associated with further changes in gray matter volume in each group. 
 
 
Conclusions 
Alcohol, tobacco and cannabis at low to moderate intake may be associated with lower gray 
matter in both ARMS subjects and healthy volunteers – possibly representing low-level 
cortical damage or change in neural plasticity. The present study does not support the 
hypothesis that ARMS subjects are at greater risk of gray matter changes associated with 
substance intake, although it is possible that at higher levels of intake, or with prolonged use, 
a differential effect may emerge. 
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Table 1: Demographic and clinical details 
 
 ARMS Controls Significance 
Age mean(SD) 25(5) 25(4) P=0.883 
Sex f/m 13/14 14/13 Fisher’s=1.0 
Ethnicity 
Caucasian/African-Caribbean/ se Asian/ 
African/ Asian/ other 
15/2/1/1/2/6 12/7/2/2/3/1 Chi sq=0.426 
Social class (parent’s occupation) 
ab,c1,c2,de, unknown 
2/6/9/3/7 2/14/6/1/4 Chi sq=0.23 
National Adult Reading Test mean(SD) 28.69(12.24) 32.89(7.96) P=0.147 
Current antipsychotic or antidepressant 
medication y/n 
5/22 0/27 Fisher’s=0.051 
Education no qualifications/ 
GCSE/A-level/ degree/higher degree  
2/13/5/7/0 0/3/16/6/2 Chi sq=0.003 
Hamilton Anxiety Scale mean(SD) 12.52(11.37) 1.85(2.63) P=0.00005 
Hamilton Depression Rating Scale 
mean(SD) 
10.51(8.85) 1.63(2.71) P=0.00002 
PANSS positive mean(SD) 11.67(3.33) 7.26(0.81) P=0.0000002 
PANSS negative mean(SD) 8.93(3.05) 7.19(0.79) P=0.007 
PANSS general mean(SD) 22.22(4.46) 16.81(1.18) P=0.000001 
 
 
 
Table 2: Intake of drugs and alcohol in ARMS subjects (n=27) and controls (n=27). Alcohol 
use is presented as units per week, tobacco  as cigarettes per day, all other drugs as occasions 
per year. 
 ARMS mean(SD) Controls mean(SD) Significance (p) 
Alcohol 
(units per 
week) 
6.96(10.58)  range=0-45 7.74(8.07) range=0-30 p=n.s. 
Tobacco 
(cigarettes 
per day) 
5.2(5.46) range=0-15 1.59(3.73) range=0-16 p<0.01 
Cannabis  
(occasions 
per year) 
67.11(223.75) range=0-1095 13.03(44.51)  range=0-178 p=n.s. 
Amphetamine 
(occasions 
per year) 
0.07(0.266) range=0-1 0.48(2.31) range=0-12 p=n.s. 
Cocaine 
(occasions 
per year) 
0.22(0.64) range=0-3 1(4.61) range=0-24 p=n.s. 
LSD 
(occasions 
per year) 
0.04(0.19) range=0-1 0(0) range=0-0 p=n.s. 
Heroin 
(occasions 
per year) 
0(0) range=0-0 0(0) range=0-0 p=n.s. 
Ketamine 
(occasions 
per year) 
0.37(0.19) range=0-1 0.37(0.19) range=0-1 p=n.s. 
Ecstasy 
(occasions 
per year) 
0.44(1.60) range=0-8 0.66(1.69) range=0-6 p=n.s. 
Other Drugs 
(occasions 
per year) 
0.22(0.97) range=0-5 0(0) range=0-0 p=n.s. 
    
 
 
 
 
 
Figure 1: inverse correlation between gray matter volume and alcohol intake (corrected for 
cannabis and tobacco intake; p=0.005). There was no significant difference between the 
relationship in controls (open circles) and ARMS subjects (closed triangles). 
 
 
 
 
 
 
 
Figure 2: inverse correlation between gray matter volume and cannabis use (log transformed 
and corrected for alcohol and tobacco intake; p<0.005). There was no significant difference 
between the relationship in controls (open circles) and ARMS subjects (closed triangles). 
 
 
 
Figure 3: inverse correlation between gray matter volume and tobacco smoking (corrected for 
cannabis and alcohol intake; p<0.005). There was no significant difference between the 
relationship in controls (open circles) and ARMS subjects (closed triangles). 
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